Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective

Most cardiovascular risk factors are things you do or accumulate. Lipoprotein(a) is mostly something you are born with — and this review marshals the genetic evidence that it is one of the largest inherited contributors to heart and valve disease that medicine has been slow to act on.

The authors lean on a particularly powerful kind of evidence: Mendelian randomization, which uses the gene variants people inherit at random to test whether a factor causes disease rather than merely tracking with it. By that standard, Lp(a) holds up. Elevated levels are causally linked to coronary artery disease and to calcific aortic valve stenosis most clearly, with further associations to peripheral artery disease, stroke, and heart failure. The scale is striking — the authors estimate up to a billion people worldwide carry levels that raise their risk.

The practical takeaway is simple and, for now, under-followed: measure Lp(a) at least once in anyone at intermediate or high cardiovascular risk. An elevated result identifies a person who warrants more aggressive control of every other modifiable factor — and who stands to benefit if the Lp(a)-lowering drugs now in trials succeed.

The status-quo resistance is candidly named. Guidelines have been slow to recommend routine testing, partly because, until recently, there was nothing specific to do about a high result — and companies without an Lp(a) drug have little reason to raise its profile.

We rate the evidence solid: robust genetic epidemiology from large cohorts, assembled by recognized experts, though it is a narrative review and the authors disclose ties to Lp(a)-drug developers. Its clinical significance is high and rising — it identifies an enormous at-risk population, and its weight will jump further if the ongoing outcome trials show that lowering Lp(a) lowers events.